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Bone protein extract is regarded as the new generation of demineralized bone matrix. The aim of this paper is to describe and 
characterize the properties of demineralized bone matrix and its new generation product in addition to its application in animal 
and human studies. Bone protein extract has features of osteoconductivity, osteoinductivity and osteogenicity, which originate 
from its unique and precise processing. It has exhibited powerful bone formation capacity both in animal experiments and in 
clinical trials by providing an optimal microenvironment for osteogenesis. Furthermore, not only does it have excellent bio-
compatibility, it also has good compatibility with other implant materials, helping it bridge the host and implanted materials. 
Bone protein extract could be a promising alternative for demineralized bone matrix as a bone graft substitute. 
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With the development of modern medical techniques, most 
orthopedic diseases can be treated effectively. However, 
most failed orthopedic operations result in the non-union of 
bone. Although autologous bone grafting can provide good 
results and has been being regarded as the gold standard 
[15], complications associated with bone graft harvesting, 
such as neurovascular injury [6], deep wound infection, 
hematoma, peritoneal perforation, ureteral injury [7,8] and 
chronic pain at the donor site [915], are still major con-
cerns [10,16]. There are many bone graft substitutes availa-
ble, including coral hydroxyapatite, calcium phosphate, 
calcium sulfate and nano-hydroxyapatite collagen; however, 
none of these possess all three features required of an opti-
mal bone biomaterial, which are osteoinductivity, oste-
oconductivity and osteogenicity.  
Demineralized bone matrix (DBM) is one of the few 
bone alternatives that exhibit osteoinductive, osteoconduc-
tive and osteogenicity characteristics [1724]. When incor-
porated with internal fixation devices and bone marrow 
mesenchymal stem cells, it can provide the ideal microen-
vironment for bone formation. In the late 19th century, Senn 
[25] was the first to report that demineralized bovine xeno-
grafts could be successfully used to repair long bone and 
cranial defects in dogs and femoral and tibial defects in hu-
mans [20]. The osteoinductive properties of DMB were not 
confirmed until a 1965 study by Urist et al. [26]. A 2009 
study by Katz et al. further increased understanding of bone 
morphogenetic proteins (BMPs) [18].  
Although DBM is deemed effective enough to be used in 
clinical applications, there are a number of limitations pre-
venting its widespread clinical use. First, there is a limit to 
the amount of allograft bone available to produce DBM [27] 
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and second, the production of DBM from other species 
raises ethical concerns. Fortunately, DBM is not spe-
cies-specific and from this bone protein extract (BPE), the 
new generation of DBM, has been removed. In 2007, the 
first commercial BPE was certified by the Food and Drug 
Administration (FDA) in the United States. This can be 
combined with a PEEK interbody cage for clinical use in 
Europe. In this review, we take an in-depth insight into the 
biological properties of BPE and their use in orthopedic 
surgery for further understanding of DBM and the new 
generation product.  
1  Biological characteristics of bone protein ex-
tract  
Bone protein extract is a new form of biomaterial extracted 
from DBM isolated from the extracellular matrix of the 
compact tissue of long bone [28]. This biomaterial is a ly-
ophilized form of collagenous matrix, consisting of collagen 
type I chains and other insoluble proteins, including trans-
forming growth factor-beta (TGF-β) superfamily, among 
other factors. It has a cotton-like appearance, with a white to 
slightly yellowish color, is processed under aseptic condi-
tions and is non-pyrogenic. 
1.1  The extraction of BPE 
BPE is created from the extracellular matrix of animal long 
bones (i.e., humerus, radius, metacarpus, femur, tibia, fibula 
and metatarsus). Although the first commercial BPE was 
made from equine bone, the first clinical BPE was derived 
from bovine bone. Because of concerns regarding bovine 
spongiform encephalopathy, it is very difficult to pursue the 
clinical application of BPE from bovine bone [29].  
BPE is aseptically produced by a series of precise and 
complicated processes. The health of donor animals and 
their exposure to pathogens is continuously monitored and 
documented throughout [30]. Cortical diaphyses of long 
bones are used to create BPE following the removal of the 
soft tissue and marrow [29]. Clean bone segments are pul-
verized and delipidated with acetone three times for 60 
minutes each at 2–7°C. Then the pulverized bone is demin-
eralized in 0.6 N hydrochloric acid three times for 60 
minutes each at 3–10°C. Following demineralization, the 
particles are washed in triple-distilled water and the ex-
tracted proteins are isolated from a 4 mol L1 guanidine 
hydrochloride solution buffered with trishydroxymethyla-
minomethane (TRIS), ethylenediaminetetraacetic acid 
(EDTA), and hydrogen chloride solution (HCl), pH 6.9, at 
15–20°C for 12.5 h for two repetitions and once for 250 min. 
After purification using a 3000 nominal molecular weight 
cut-off ultra filter, the extracted proteins are lyophilized, 
resulting in a cotton-like appearance [31,32] (Figure 1).   
Compared with the production of traditional DBM, the 
production of BPE has the following characteristics which 
are beneficial for its use: (i) The bone used is sourced from 
documented animals; (ii) the production process is precisely 
designed and rigidly observed; (iii) unlike the traditional 
single demineralization step, there are two dematerialization 
steps in the processing of BPE, using both HCl and EDTA 
[26,33,34]; (iv) the extracted proteins are lyophilized in the 
final step. Owing to these specialized processing steps, BPE 
possesses unique features making it a more ideal bone graft 
substitute than traditional DBM. 
1.2  Composition analysis of bone protein extract 
Although DBM was first used in the late 19th century and 
later shown to be effective for bone fusion in 1965, its use  
 
 
Figure 1  Extraction process of bone protein extract. HCl, hydrochloric acid; EDTA, ethylenediaminetetraacetic acid. 
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in promoting bone formation was not fully examined until 
BMPs were discovered by Urist in 1975. Wildemann et al. 
[35] demonstrated that DBM, which has been demineralized 
and sterilized by different processing methods, retained dif-
ferent amounts of insoluble proteins by comparing three 
commercially available DBMs. However, in those studies, 
BMP-2 was detected at its highest level in all DBMs tested. 
Honsawek et al. [36] measured and quantified BMP-4 in 
DBM from human bone, and they demonstrated that the 
osteoinductive capacity of DBM increased corresponding to 
BMP-4 concentration by heterotopic ossification in athymic 
mice. Bae et al. [37] compared BMPs in several commercial 
DBMs and found that BMP-2 and BMP-7 could be detected 
in all products at different concentrations. The different 
extraction methods used in the production of each DBM 
were considered to be the most important factor in deter-
mining the BMP content of DBM. William et al. [21] also 
measured BMP-4 in DBM, but found it was lower than 
BMP-2 and BMP-7. All three BMPs were confirmed by 
mass spectrometry or ELISA in BPE, but were not detected 
by western blotting by Nienhuijs et al. [32]. In their study, 
BMP-2 was approximately one hundred-fold higher in BPE 
than in DBM. Thus, to date, at least three BMPs have been 
verified to be present in BPE. With the development of this 
technique, more BMPs may be detected in BPE by 
high-tech precision instruments in the near future. 
Regarding bone formation, BMPs, TGF-β, a member of 
the TGF superfamily, also plays an important role in bone 
regeneration. Several TGF-βs have been detected in both 
DBM and BPE. Carrington et al. [38] demonstrated that 
TGF-βs were present in DBM following extraction with 
EDTA-guanidine hydrochloride, but not guanidine hydro-
chloride alone. Wildemann et al. [35] verified that TGF-β1 
was present in all the three commercial DBMs, although it 
was at a low level. Katz et al. [18] found a weak Spearman 
correlation between the level of TGF-β1 in the DBM of 
donors’ bone and its capacity for bone formation. However, 
we believe that multivariate correlation analysis should be 
used as TGF-β1 was just one of the microenvironmental 
factors contributing to enhanced bone formation. Using 
mass spectrometry and western blotting simultaneously, 
Nienhuijs et al. [32] found that TGF-β1 and TGF-β2 were 
all present in BPE, with TGF-β1 being over two hun-
dred-fold higher than in DBM.  
TGF-β1 and TGF-β2 are the main insoluble proteins 
contributing to the osteoinductive capacities of BPE. Indeed, 
there are some known and undetected trace proteins present 
in BPE, such as insulin-like growth factor 1(IGF-1), which 
also play a role in creating a suitable microenvironment for 
bone formation. However, these factors are not functional 
unless they are present in osteoconductive media, mainly 
type I collagen, where they can exert their functions. In the 
early 1970s, Bachra [39] verified that bone collagen was a 
good nucleation catalyst for mineral deposition compared 
with rat tail collagen. Hanson et al. [40] studied the stereo-
specific features of type I collagen in human bone, which is 
convenient for collagen mineralization. Although there has 
been no scientific paper on type I collagen in BPE, it has 
been documented by the FDA. 
Thus, BPE is composed of a collagenous matrix, includ-
ing type I collagen chains and several other insoluble pro-
teins, such as BMP-2, BMP-3, BMP-7, TGFβ-1, TGFβ-2, 
IGF-1 and other unknown factors. These components en-
dow BPE with all the bone formation activities, as it dis-
plays good osteogenicity, osteoconductivity and osteoin-
ductivity. Compared with other mono-factors such as 
BMP-2, BPE has the following unique advantages: (i) Ani-
mal bone is abundant, and the health and exposure to path-
ogens of donor animals is continuously monitored and 
documented, which enable the safe and effective mass pro-
duction of BPE; (ii) most mono-factors are only effective in 
very high concentrations, with several authors having re-
ported on heterotopic ossification induced by BMPs 
[4143]. BPE has not be shown to have this effect, although 
the dose-effect relationship of BPE is difficult to define in 
different patients; (iii) besides autologous bone grafting, 
DMB and this new generation product are the only products 
that can provide optimal microenvironments for bone for-
mation.  
1.3  Bioactivity 
The ideal bone graft material must possess three key prop-
erties; osteoconductivity; osteoinductivity: and osteogenici-
ty [44]. Autologous bone grafting is the only procedure that 
currently meets all three of these requirements. However, 
BPE shows good characteristics of all the three of these 
properties, which may be increased by coupling with stem 
cells for more powerful osteoinductive and osteoconductive 
capacities, which is far beyond other DBMs. 
The osteoinductivity of a graft material is its ability to 
facilitate the recruitment and differentiation of stem cells 
into osteoblasts (the bone-forming cells) [44]. Although 
stem cell recruitment has not been extensively examined in 
orthopedics, Urist [26] demonstrated that three distinct pop-
ulations of cells were recruited in the host tissue and among 
these were osteoprogenitor cells, which are regarded as 
stem cells. Using BPE in the anterior spinal fusion cage, Li 
et al. [45] found that it produced the same effects as autol-
ogous bone grafting in achieving fusion and the percentage 
of new bone formation. The excellent effectiveness of BPE 
in this study was believed to result from the migration and 
differentiation of mesenchymal cells from the vertebral 
bodies [45]. This hypothesis was confirmed in similar ex-
periments by Walboomers et al. [46]. A further study 
demonstrated that the mechanisms of bone formation with 
BPE were related to increased penetration of blood vessels 
into these materials than that into other bone substitutes, 
leading to a rapid enrichment of osteoblasts and an induc-
tion of membranous bone formation [47]. In combination 
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with DBM from human bone, Kuvat et al. [48] used BPE as 
an osteoinductive material in clinical maxillofacial surgery 
to good results, which were evaluated by clinical and histo-
pathological examination.  
Osteoconductivity is the ability of graft materials to pro-
vide biocompatible scaffolding that supports new bone for-
mation and subsequent growth [44]. The interaction be-
tween cells and bone substitutes is reliant on the attachment, 
adhesion and spreading of bone cells on the material, and 
the ability to further influence cell proliferation and differ-
entiation. Type I collagen, which contains Arg-Gly-Asp 
(RGD) sequences, is the ideal biomaterial component 
[4951]. Several studies have verified that collagen can 
enhance the adhesion and contact guidance of osteoblasts 
inoculated onto the composite surface through specific 
RGD sequences that mediate interaction between integrins 
and the substrate surface thereby promoting cell adhesion 
[4951]. Collagen in DBM has also been confirmed to have 
osteoconductive functions [39]. Hanson et al. [40] found 
that the stereospecific features of bone collagen at the mo-
lecular level, such as the pattern of cross-linking and the 
interchain placement of bonds, were markedly different 
from other tissue collagens, in particular type I collagen, 
which may alter collagen mineralization. As BPE is a ly-
ophilisate in collagenous matrix form, consisting of colla-
gen type I chains and other insoluble proteins, the oste-
oconductive capacity is obvious.  
An osteogenic bone graft contains cellular elements at 
different stages of osteoblastic differentiation, including 
osteoprogenitor cells, that are capable of synthesizing new 
bone at the fusion site, thus forming new bone directly 
[25,44]. Currently, none of the bone substitutes available 
have the osteogenic capacity that autogenous bone grafting 
has, and BPE is certainly no exception. However, when 
incorporated with stem cells, DBM has increased bone 
forming abilities, as the stem cells impart a semi-osteogenic 
capacity to it. Becerra et al. [52] demonstrated that bone 
marrow stromal cells are more osteogenic in the presence of 
DBM, whereas they tended to form other colonies, such as 
fibroblastic, epithelial or smooth muscle cells, without it. 
The combined osteogenicity of DBM and stem cells was 
further studied by many authors. In their experiments, the 
extent of bone formation induced by DBM combined with 
stem cells was obviously increased when compared with 
that induced by stem cells or DBM alone [5360]. BPE 
could increase the proliferation of undifferentiated stem 
cells and accelerate the differentiation of pre-mature osteo-
blastic cells in vitro [61]. To the best of our knowledge, no 
report has been published on the use of combined stem cells 
and BPE for treatment in vivo.  
1.4  Stem cell interaction 
DBM, and in particular its new generation product BPE, has 
been shown to promote the proliferation and differentiation 
of stem cells. Kasten et al. [62] seeded bone marrow stro-
mal cells (MSCs) on calcium-deficient hydroxyapatite 
(CDHA), β-tricalcium phosphate (β-TCP) and DBM. DBM 
was an excellent matrix for MSCs according to the cells 
seeding efficacy or osteocalcin expression, compared with 
synthetic materials. These findings were supported by a 
number of other studies [6265]. By culturing human mes-
enchymal stem cells over-expressing human telomerase 
reverse transcriptase (hMSC-TERT) in plates coated with 
BPE at different concentrations, Woo et al. [61] demon-
strated that BPE could increase the proliferation of undif-
ferentiated hMSC-TERT cells and accelerate osteoblastic 
differentiation of hMSC-TERT cells with a limited effect on 
proliferation. It was also observed by El-Sabban et al. [66] 
that BPE could induce osteoblastic differentiation of in vitro 
expanded BMSCs.   
Accordingly, the osteoinductive and semi-osteogenic ca-
pacities enable BPE to induce the proliferation and differen-
tiation of stem cells, thus promoting bone formation. How-
ever, these effects are not just seen on stem cells but on 
other cells, such as L-929 fibroblasts and the mus-
cle-derived cell line C2C12 [67,68]. One point worth noting 
is that unlike other DBM, the interaction between BPE and 
stem cells, to the best of our knowledge, has not been 
shown in vivo, and thus further studies are warranted. 
1.5  Combination of other materials 
BPE has a poor ability to retain its shape in vivo without 
providing mechanical support. Thus, a carrier is needed to 
help define the shape of the implant, while also retaining the 
proteins in the specific area for an adequate time period [69]. 
Owing to this, it is not worth applying BPE alone for large 
bone defects even though it is much cheaper than rhBMPs. 
In addition, using too high a concentration could theoreti-
cally result in heterotopic ossification, which can occur with 
BMPs [4143,70]. More importantly, as BPE is made from 
a natural organism, it has been verified to have good bio-
compatibility with host tissue. 
Furthermore, BPE has good synergistic actions with oth-
er materials. A canine study demonstrated that fibrous tissue 
covered β-TCP implants, which hindered implant degrada-
tion and new bone formation. β-TCP in combination with 
BPE was protected from this phenomenon and gave a 
two-fold increase in mechanical implant fixation [71]. Some 
authors observed a synergistic effect between BPE and car-
boxymethylcellulose (CMC), where they reported that a 3% 
CMC gel could act as carrier or bulking agent either in gel 
or lyophilized form [28,69]. However, we should not expect 
the best results for the use of BPE in either of those condi-
tions. In vitro, the combination of BPE with a collagen hy-
droxyapatite composite scaffold resulted in a synthetic bone 
graft substitute, which could be completely remodeled into 
vital bone tissue [72]. However, the same carrier, which was 
derived from an equine source, unexpectedly inhibited the 
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osteoinductive capacity of BPE in vivo as a result of an in-
flammatory response [73]. To the best of our knowledge, 
this is the first and only report to date where BPE had a 
negative effect of bone formation.  
Although several authors have studied different carriers 
for BPE, more research needs to be performed to determine 
the best carrier for orthopedic clinical applications. Further 
investigations should focus on determining the most suita-
ble carrier, both in basic research and multicenter clinical 
studies. 
1.6  Molecular mechanism of bone formation 
Bone formation is a complex, sequential and overlapping 
process. Although many factors have been verified to ac-
celerate bone formation, the mechanism and their interac-
tions are still poorly understood. Zou et al. [74] pioneered 
this field by using microarray technology to examine 
gene-expression profiles during anterior lumbar interbody 
fusion (ALIF) after implantation of different graft materials, 
including BPE, recombinant human bone morphogenetic 
protein-2 (rhBMP-2) and autograft bone. They found that 
different pathways induced different kinds of bone for-
mation at different time points and in different situations. 
Compared with autograft bone, rhBMP-2 induced membra-
nous ossification via recruitment, proliferation and differen-
tiation of osteoblastic progenitor cells by upregulating vari-
ous factors, such as prostaglandin endoperoxide H syn-
thase-2 (PGHS-2), insulin-like growth factor binding pro-
tein-2 (IGFBP-2), vascular endothelial growth factor 
(VEGF) and chemokines. In contrast, BPE resulted in en-
dochondral ossification via the upregulation of cartilage-  
related genes, which is similar to autograft bone.  
Therefore, BPE, distinct from other artificial bone graft 
materials, can provide the most optimal biological microen-
vironment for bone formation. With the technology availa-
ble, it is currently not possible to build a biological micro-
environment without using natural bone because of the 
complexity of bone. Some factors, such as rhBMP-2, may 
improve bone formation, but it does not reform in a natural 
manner. Thus, as BPE originates from natural bone, it may 
be a better choice.  
1.7  Biocompatibility 
Bone is known to possess low immunogenicity. Thus, bone 
allograft transplantation has been quite successful for sever-
al decades, with cryopreserved bone in particular being 
quite effective [7577]. Even today, this treatment remains 
necessary under certain circumstances. BPE also possesses 
the characteristic of having lower immunogenicity. BPE 
was shown to have good cytocompatibility, in combination 
with human mesenchymal stem cells, as cells could adhere, 
proliferate and differentiate into the osteoblastic lineage 
[72]. Although BPE is made from bovine or equine sources, 
it still has excellent biocompatibility when transplanted into 
different species, including humans (Table 1). Furthermore, 
BPE is compatible with titanium implants, which can bridge 
the inorganic material and local tissue [45,46,7880]. 
Therefore, the good biocompatibility of BPE can not only 
accelerate bone formation, but also enhance the stability of 
the implants by being compatible with both the bone tissue 
and the implant. 
Table 1  Bone protein extract used in different animal experiments 
Author Journal Animal(n) Observation time Comments 
Baas et al. [101] J Biomed Mater Res A Dog(9) 4 weeks No complications 
Ding et al. [102] 
J Biomed Mater Res B 
Appl Biomater 
Sheep(8) 9 weeks 
Complications of a paralytic hind leg in one sheep, no related to 
BPE 
Jensen et al. [28] Open Orthop J Sheep(6) 16 weeks No complications 
Nienhuijs et al. [29] 
J Biomed Mater Res B 
Appl Biomaterials 
goat(6) 9 weeks Swelling for two weeks, the animals ate normally 
Nienhuijs et al. [73] Tissue Eng Part A rat(18) 12 weeks Redness and swelling of the skin but good health 
Foldager et al. [91] Bone Pig(12) 8 weeks One infection 
Zou et al. [74] Biomaterials Pig(18) 8 weeks No comments 
Baas et al. [71] Acta Orthop Dog(10) 4 weeks 
One dog was excluded from the study due to a postoperative frac-
ture of the right humerus, the remaining 9 dogs were without   
complications 
Foldager et al. [90] Spine Pig(18) 8 weeks One infection 
Li et al. [89] 
J Biomed Mater Res B 
Appl Biomater 
Pig(10) 12 weeks No comments 
Li et al. [78] Spine Pig(12) 12 weeks Without major complications 
Baas et al. [79] Acta Orthop Dog(16) 4 weeks No postoperative complications 
Nienhuijs et al. [80] Biomaterials rat(18) 12 weeks 
One animal died because of anaesthesia, other rats appeared to be 
in good health 
Li et al. [45] Spine Pig(12) 12 weeks 
Two of the pigs were terminated at the fourth week: one resulting 
from abdominal wall infection and another resulting from de-
creased activity probably caused by pain 
Walboomers et al. [46] Biomaterials rat(18) 12 weeks Good health 
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2  Animal study 
Many experiments in animals have confirmed the bone 
formation effects of DBM. To find the best way for bone 
decalcification, Urist [26] performed experiments in over 
200 rabbits and successfully verified these results in several 
other animal species. Almost all subsequent experiments 
involving DBM were based on his original findings, in-
cluding BPE. As the new generation of DBM, BPE has ex-
cellent performance in bone formation. Several studies have 
demonstrated that it has the ability to induce ectopic bone 
formation in different animal models [46,69,73,80,81]. 
2.1  Spinal fusion 
Used in several animal spinal fusion models, traditional 
DBM has been reported to result in good bone formation 
[8285]. However, few studies could confirm that DBM is 
more or even as effective as autografts and thus it could not 
be recommended to totally replace autografting [86]. Indeed, 
BPE also has not been verified to have a stronger bone for-
mation capacity than the ‘gold standard’ autografting. 
However, BPE is different from traditional DBM, and a 
series of studies focusing on spinal fusion using BPE have 
shown promising results. The lumbar spine fusion model 
was first built in pigs (Figure 2), which has a reported fu-
sion rate close to that of humans [87,88]. Spinal fusion was 
evaluated by radiography, micro-CT and histomorphometry, 
and they concluded that BPE achieved the same fusion rate 
and the same percentage of new bone formation as that of 
an autologous iliac bone graft in this demanding porcine 
anterior spinal fusion model after 12 weeks (Figures 3 and 4) 
[45,78,89]. Following these studies, researchers introduced 
positron emission tomography/computed tomography (PET/ 
CT) as a new evaluation method (Figure 5) [90] and ex-
perimentally investigated the mechanism by examining os-
teogenic pattern, gene expression and the pathway involved 
in new bone formation induced by BPE [74,91].  
2.2  Bone defects 
To date, there has been no research reporting on the treat- 
ment of large bone defects with BPE. The main reason be-
hind this may be that it may be too difficult for BPE alone  
 
 
Figure 2  Plain radiographs (A and B) and 3D reconstruction image (C). The cage with bone protein extract and stable construct in a lumbar spine fusion 
model of pigs. 
 Zhou Z Y, et al.   Sci China Life Sci   December (2012) Vol.55 No.12 1051 
 
Figure 3  Images of micro-CT of a pig model. The metallic walls of the cage had been cut apart and the bony struts inside the cage were left intact. Both 
bone protein extract (A1) and autograft (A2) achieved solid fusion with longitudinally organized trabeculae, as evidenced by 2D images (A1 and A2) and 3D  
reconstructions (B1 and B2). Reproduced from Li et al. [45] with permission from Wolters Kluwer Health. 
to deal with an injury of this magnitude without a carrier for 
structural support. Even so, several authors have reported 
the effect of BPE in smaller bone defects. Kloss et al. 
[92,93] applied BPE in treating a porcine forehead defect 
and the results showed an acceleration of bone regeneration 
until 26 weeks, which were comparable with autogenous 
bone grafting. Schlegel [94] observed similar results in his 
experiments. By placing BPE in 5-mm cortical bone defects 
in sheep long bone, Huffer et al. [30] confirmed that both 
bovine and equine BPE was equivalent to autografting, and 
superior to β-TCP, in treating a sheep model. Jensen et al. 
[28] also demonstrated in sheep that BPE had bone regener-
ative effects in drill defects on the humerus or skull. 
Thus, BPE obviously possesses the capacity for treating 
bone defects. Designing a perfect carrier would be a partic-
ular advantage for its use in the treatment of large bone de-
fects [72]. 
2.3  Artificial joint revision 
In general, autologous bone transplantation is not used in 
initial joint replacement as there is little bone that can be 
easily harvested from the operation site. For revision sur-
gery, the situation is entirely different. Artificial joint revi-
sion requires huge amounts of bone graft material. Autolo-
gous bone is regarded as the best bone graft material; how-
ever, it is not easy to obtain enough bone for this kind of 
operation. Therefore, bone graft substitutes must be used 
and they should have good biocompatibility with the new 
prosthesis. Fortunately, Baas et al. [71,79,95] thoroughly 
studied the biocompatibility of BPE for bone repair. They 
designed porous-coated titanium alloy implants, which they
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Figure 4  Micrographs from histological sections of pig 12 after three months. Both at the autograft level (A) and bone protein extract level (B), histologic 
fusion with the trabeculae orientated in the longitudinal direction as a result of mechanical loading (basic fuchsin and light green stain, original magnification  
×1.25). Reproduced from Li et al. [45] with permission from Wolters Kluwer Health. 
 
Figure 5  T2 map of a pig model. Regions of interest are marked inside the cages. 1, autograft; 2, bone protein extract; 3, INFUSE. Reproduced from Fold-
ager et al. [90] with permission from Wolters Kluwer Health. 
combined with different kinds of bone substitute material, 
and placed the implants in the lateral proximal humerus of 
dogs. Using mechanical testing and histological sectioning, 
authors reported encouraging results showing that BPE 
could improve mechanical implant fixation, eliminate fi-
brous tissue formation almost completely, and increase the 
osseous anchorage and bone remodeling of allografted po-
rous-coated titanium implants. The promising experimental 
results of the use of BPE offer a new way to augment revi-
sion prosthesis. 
In summary, BPE induces good bone formation in animal 
experiments at a number of different surgical sites. All of 
these studies have provided the basic data for the clinical 
application of BPE. Aside from the present use of BPE in 
the clinic, further studies should focus on the following are-
as: (i) Designing a carrier for BPE and identifying dose- 
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effect relationship; (ii) stimulating osteogenic differentia-
tion of stem cells with BPE in vivo; (iii) injecting BPE with 
an available carrier in the area of the bone defect at different 
time points; (iv) combining BPE with antibiotics for the 
treatment of osteomyelitis and, in particular, bone tubercu-
losis. 
3  Clinical applications 
Although the use of DBM as a bone substitute in clinical 
applications was first suggested over a century ago, it was 
not until recently that it received FDA approval. The choice 
of raw material for DBM has always been a subject of fe-
verish debate. Obviously, there are two sources, animal 
(xenograft) or human (allograft) bone. In theory, human 
bone is better but there are a number of limiting factors. 
First, disease could be transmitted from the donor to the 
recipient [96]. Second, the limited quantity of human bone 
prevents its large-scale commercial production. In contrast, 
animal bone may be a good alternative. Thus, BPE emerged 
as the solution. 
BPE was first reported to be used clinically in spinal fu-
sion in 2002 [97]. When BPE was filled in carbon cages, the 
fusion rate was 98.6%, higher than that achieved using an 
iliac crest bone graft. However, there have been no reports 
on the clinical use of BPE in the treatment of long bone and 
joint fractures, as a suitable carrier has not been designed 
yet. 
BPE could also be used in other areas of surgery, in par-
ticular in maxillofacial surgery. Rupprecht et al. [98] treated 
the nonunion situation subsequent to primary mandible 
fracture by the application of BPE, compared with iliac 
crest bone grafts. The results demonstrated that BPE accel-
erated bone formation, especially in the initial stages of 
bone healing. Furthermore, antibiotic-containing BPE was 
suitable as a bone replacement material for the treatment of 
nonunion bone defects, suggesting that this joint action 
could be effective for osteomyelitis. Another BPE success-
fully applied in oral surgery was reported by Kuvat et al., 
which verified the effects of BFE not only by imaging but 
also by histological evaluation, which is not possible in hu-
mans generally [48]. Camargo [99] also obtained similar 
positive results. Although few studies have examined the 
use of BPE, it has been confirmed to have a strong capacity 
for bone formation, which is promising for its future appli-
cation in clinical practice. 
4  Perspective for further application 
A biomaterial is a substance that has been engineered to 
take a form, which alone or as part of a complex system, 
can direct the course of any therapeutic or diagnostic pro-
cedure, in human or veterinary medicine, by controlling 
interactions with components of living systems [100]. BPE 
is an ideal biomaterial for bone formation because of the 
microenvironment it offers with its powerful osteogenic 
ability, which cannot be currently re-created by other means. 
Owing to this unique feature, BPE may be a very encourag-
ing bone graft material for use in different areas. A few 
suggestions on the use of BPE are as follows:  
The combination of BPE with other biomaterial or/and 
stem cells is the basis and precondition for its widespread 
application. 
Spinal fusion: the good effect of BPE in ALIF has been 
observed in animal experiments and a few clinical reports; 
animal and pre-clinical experiments are necessary to deter-
mine its application in posteriolateral fusion. 
Bone defects: designing a perfect carrier is imperative; 
the synergic effects of BPE and stem cells should be im-
plemented during early, middle and later stages of bone 
formation in vivo; the combined effects of BPE and antibi-
otics (anti-tuberculosis medication in particular) on bone 
formation or stem cells should also be examined.  
Artificial joint revision: whether BPE accelerates bone 
formation on the surface of different prostheses should be 
defined; the effects of BPE with impacted bone grafting 
around the joint should be measured in animal experiments. 
5  Conclusion  
BPE was regarded as the new generation of demineralized 
bone matrix because of its special and precise extracting 
process and unique biological characteristics. It has been 
verified to have bone formation capabilities by creating a 
microenvironment for osteogenesis. At present, BPE re-
mains the most promising material for performing success-
ful bone grafts. 
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